Novel Cell Sorting and Separation Market: Focus on Acoustophoresis, Buoyancy-activated, Dielectrophoresis, Magnetophoretics, Microfluidics, Optoelectronics, Photoacoustics, Traceless Affinity and Other Technologies, 2019-2030

Novel Cell Sorting and Separation Market: Focus on Acoustophoresis, Buoyancy-activated, Dielectrophoresis, Magnetophoretics, Microfluidics, Optoelectronics, Photoacoustics, Traceless Affinity and Other Technologies, 2019-2030

Advances in the fields of cell biology and regenerative medicine have led to the development of various cell-based therapies, which, developers claim, possess the potential to treat a variety of clinical conditions. In 2018, it was reported that there were more than 1,000 clinical trials of such therapies, being conducted across the globe by over 900 industry players. Moreover, the total investment in the aforementioned clinical research efforts was estimated to be around USD 13 billion. Given the recent breakthroughs in clinical testing and the discovery of a variety of diagnostic biomarkers, the isolation of one or multiple cell types from a heterogenous population has not only become simpler, but also an integral part of modern clinical R&D. The applications of cell separation technologies are vast, starting from basic research to biological therapy development and manufacturing. However, conventional cell sorting techniques, including adherence-based sorting, membrane filtration-based sorting, and fluorescence- and magnetic-based sorting, are limited by exorbitant operational costs, time-consuming procedures, and the need for complex biochemical labels. As a result, the use of such techniques has, so far, been restricted in the more niche and emerging application areas.

Over the years, extensive research in the field of flow cytometry has enabled the development of a variety of novel technologies that are capable of efficiently isolating cells from tissue samples and / or heterogenous cell populations. In fact, since 2014, over 3,000 patents were reported to have been filed / granted related to such advanced techniques, indicating the rapid pace of innovation in this domain. Developers of the aforementioned technologies claim that these new techniques offer numerous benefits, including fast and precise cell sorting, reduced sample requirement, improved portability, reduced risk to cell viability, and negligible need for expensive biochemical / magnetic labels. Moreover, they have been shown to be compatible for use across a myriad of applications, including research studies (bacteriology, immunology, stem cell research, and viral titering and infectivity), biomedical diagnostics (circulating tumor cell detection, in vitro fertilization, and non-invasive prenatal diagnosis), biological therapy-related process operations (bio-banking, drug discovery, sample preparation, single cell sequencing, and tumor cell characterization), and cell-based therapeutics (B- or T-cell immunotherapies). Consequently, these techniques have captured the interest of several stakeholders in the biopharmaceutical industry. It is also worth highlighting that stakeholders in this domain have received significant support from both private and public investors.

SCOPE OF THE REPORT
The ‘Novel Cell Sorting and Separation Market: Focus on Acoustophoresis, Buoyancy-activated, Dielectrophoresis, Magnetophoretics, Microfluidics, Optoelectronics, Photoacoustics, Traceless Affinity and Other Technologies, 2019-2030’ report features an extensive study of the current landscape and future outlook of the growing market for novel cell sorting and separation technologies (beyond conventional methods). The study presents detailed analyses of cell sorters, cell isolation kits, and affiliated consumables and reagents, that are based on the aforementioned technologies. Amongst other elements, the report features:

A detailed assessment of the current market landscape, featuring a comprehensive list of over 220 innovative cell sorters, cell isolation kits, and affiliated consumables and reagents, along with information on their respective specifications (such as size, weight, cell flow rate, cell sort rate, cell analysis rate, cell purity and viability, process time, and operating temperature and pressure), cell sorting technology (acoustophoresis, buoyancy-activated, dielectrophoresis, magnetophoretics, microfluidics, optoelectronics, photoacoustics, traceless affinity, and others), type of cell (animal cells, cancer cells, immune cells, microbial cells, red blood cells / platelets, stem cells, and others), cell separation approach (positive selection, negative selection and depletion), basis for separation (cell morphology and physiology, cell size and density, surface biomarkers, surface charge and adhesion, and others), and end use / application (research studies, biomedical diagnostics, biological therapy-related process operations, and cell-based therapeutics).

An insightful company competitiveness analysis, taking into consideration the supplier power (based on size of employee base and experience in this segment of the industry) and portfolio-related parameters, such as number of products offered, number of target cells, end use(s) / application(s), and key product specification(s).

Comprehensive profiles of key industry players (shortlisted on the basis of company competitiveness analysis scores) that are currently offering novel cell sorters / consumables and cell isolation kits, featuring an overview of the company, its financial information (if available), and a detailed description of its proprietary product(s). Each profile also includes a list of recent developments, highlighting the key achievements, partnership activity, and the likely strategies that may be adopted by these players to fuel growth in the foreseen future.

An in-depth analysis of the patents that have been filed / granted related to novel cell sorting and separation technologies, since 2014. It highlights the key trends associated with these patents, across patent type, regional applicability, CPC classification, emerging focus areas, leading industry players (in terms of number of patents filed / granted), and current intellectual property-related benchmarks and valuation.

A detailed publication analysis of more than 200 peer-reviewed, scientific articles that have been published since 2014, highlighting the research focus within the industry. It also highlights the key trends observed across the publications, including information on innovative technologies, potential application areas, target disease indications, type of cell, and analysis based on various relevant parameters, such as year of publication, and most popular journals (in terms of number of articles published in the given time period) within this domain.

An analysis of the partnerships that have been established in the domain, in the period 2014-Q1 2019, covering R&D collaborations, licensing agreements, distribution agreements, mergers / acquisitions, asset purchase agreements, product development agreements, product utilization agreements, and other relevant deals.

An analysis of the investments made at various stages of development, such as seed financing, venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings, by companies that are engaged in this field.

An analysis to estimate the likely demand for novel cell sorting products and solutions across key application areas, including research studies, clinical diagnostics, cell-based therapeutics, and other applications, in different global regions for the period 2019-2030.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the novel cell sorting and separation market. Based on multiple parameters, such as potential application areas, likely adoption rate and expected pricing, we have provided an informed estimate on the likely evolution of the market, over the period 2019-2030. In addition, we have provided the likely distribution of the current and forecasted opportunity across [A] potential application areas (research studies, clinical diagnostics, cell-based therapeutics, and other applications), [B] end users (academic institutes, clinical testing labs, hospitals, and commercial organizations), [C] type of offering (cell sorters, and consumables and isolation kits), [D] cell sorting technology (buoyancy-activated, magnetophoretics, microfluidics, optoelectronics, and other advanced technologies), [E] type of cell (adult stem cells, CAR-T cells, circulating fetal cells, circulating tumor cells, dendritic cells, embryonic stem cells, insect cells, induced pluripotent stem cells, microbial cells, sperm cells, TCR cells, TILs, and tumor cells / cancer cells), [F] size of cell (< 5 µm, 5-10 µm, 10-15 µm, 15-25 µm, and > 25 µm), and [G] key geographical regions (North America, Europe and Asia-Pacific). In order to account for the uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios portraying the conservative, base and optimistic tracks of the industry’s evolution.

The opinions and insights presented in this study were also influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals (in alphabetical order of organization names):
John Younger (Co-founder and Chief Technology Officer, Akadeum Life Sciences)
Sean Hart (Chief Executive Officer and Chief Scientific Officer, LumaCyte)
Soohee Cho (Product Manager, Namocell)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include
Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts’ views

While the focus has been on forecasting the market till 2030, the report also provides our independent view on various non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

CHAPTER OUTLINES
Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of novel cell sorting and separation market in the mid-long term.

Chapter 3 is an introductory chapter that presents a general overview of cell sorting and separation, including a brief history of development, and information on the basic components and principle of operation of a cell sorter. Further, it features a detailed discussion on conventional cell separation techniques and the various challenges associated with their use across different application areas. The chapter also includes detailed sections on the novel cell sorting and separation technologies (such as acoustophoresis, buoyancy-activated, dielectrophoresis, magnetophoretics, microfluidics, optoelectronics, photoacoustics, traceless affinity, and others), highlighting their advantages and challenges. Further, it features a discussion on the key growth drivers and roadblocks related to modern cell sorting technologies, as well as upcoming trends that the field is expected to witness in the coming years.

Chapter 4 includes information on more than 220 innovative cell sorters, cell isolation kits, and affiliated consumables and reagents, along with details on their respective specifications (such as size, weight, cell flow rate, cell sort rate, cell analysis rate, cell purity and viability, process time, and operating temperature and pressure), cell sorting technology (acoustophoresis, buoyancy-activated, dielectrophoresis, magnetophoretics, microfluidics, optoelectronics, photoacoustics, traceless affinity, and others), type of cell (animal cells, cancer cells, microbial cells, red blood cells / platelets, stem cells, and others), cell separation approach (positive selection, negative selection and depletion), basis for separation (cell morphology and physiology, cell size and density, surface biomarkers, surface charge and adhesion, and others), and end use / application (research studies, biomedical diagnostics, biological therapy-related process operations, and cell-based therapeutics). The chapter also highlights the contributions of various companies engaged in this domain, presenting detailed analyses, based on their year of establishment, size of employee base, geographical presence, and type of offering.

Chapter 5 features an insightful competitiveness analysis of the companies engaged in novel cell sorting and separation domain, based on various parameters, such as number of products offered, number of target cells, end use(s) / application(s), and key product specification(s). In the chapter, stakeholder entities have been plotted on a 2X2 matrix, featuring a company’s Supplier Power (based on size of employee base and experience in this segment of the industry) and Company Competitiveness as the two axes.

Chapter 6 includes elaborate profiles of key industry players (shortlisted on the basis of company competitiveness analysis scores) that are offering novel cell sorters / sorting technologies; each profile features an overview of the company, its financial information (if available), and a detailed description of its proprietary product(s). Each profile also includes a list of recent developments, highlighting the key achievements, partnership activity, and the likely strategies that may be adopted by these players to fuel growth, in the foreseen future.

Chapter 7 includes detailed profiles of key industry players (shortlisted on the basis of company competitiveness analysis scores) that are offering novel consumables and cell isolation kits; each profile features an overview of the company, its financial information (if available), and a detailed description of its proprietary product(s). Each profile also includes a list of recent developments, highlighting the key achievements, partnership activity, and the likely strategies that may be adopted by these players to fuel growth, in the foreseen future.

Chapter 8 provides an in-depth patent analysis to provide an overview of how the industry is evolving from the R&D perspective. For this analysis, we considered those patents that have been filed / granted related to novel cell sorting and separation technologies, since 2014. The analysis also highlights the key trends associated with these patents, across patent type, regional applicability, CPC classification, emerging focus areas, leading industry players (in terms of number of patents filed / granted), and current intellectual property-related benchmarks and valuation.

Chapter 9 presents a detailed publication analysis of more than 200 peer-reviewed, scientific articles that have been published since 2014, highlighting the research focus within the industry. It also highlights the key trends observed across the publications, including information on innovative technologies, potential application areas, target disease indications, type of cell, and analyses based on various relevant parameters, such as year of publication, and most popular journals (in terms of number of articles published in the given time period) within this domain.

Chapter 10 features an elaborate analysis and discussion of partnerships / collaborations that have been established in this domain in the period 2014-Q1 2019. It includes a brief description of various types of partnership models (such as R&D collaborations, licensing agreements, distribution agreements, mergers / acquisitions, asset purchase agreements, product development agreements, product utilization agreements, and others) that have been employed by stakeholders within this domain. It also consists of a schematic representation showcasing the players that have established the maximum number of alliances related to novel cell sorting and separation technologies. Furthermore, we have provided a world map representation of all the deals inked in this field, highlighting those that have been established within and across different continents.

Chapter 11 provides information on funding instances and investments that have been made within the novel cell sorting and separation domain. The chapter includes details on various types of investments (such as seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings) received by companies in the period 2014-Q1 2019, highlighting the growing interest of the venture capital community and other strategic investors in this domain.

Chapter 12 provides an overview of the demand for novel cell sorting products and solutions across key application areas, including research studies, clinical diagnostics, cell-based therapeutics, and other applications, in the contemporary market. In order to estimate the aforementioned demand, we considered the number of ongoing / completed research studies, diagnostic tests and cell-based therapies under development across different geographies. We also estimated the likely adoption of such products and solutions across key application areas, over the period 2019-2030.

Chapter 13 features a comprehensive market forecast, highlighting the future potential of novel cell sorting and separation market till 2030, based on multiple parameters, such as potential application areas, likely adoption rate and expected pricing. In addition, we estimated the likely distribution of the current and forecasted opportunity across [A] potential application areas (research studies, clinical diagnostics, cell-based therapeutics, and other applications), [B] end users (academic institutes, clinical testing labs, hospitals, and commercial organizations), [C] type of offering (cell sorters, and consumables and isolation kits), [D] cell sorting technology (buoyancy-activated, magnetophoretics, microfluidics, optoelectronics, and other advanced technologies), [E] type of cell (adult stem cells, CAR-T cells, circulating fetal cells, circulating tumor cells, dendritic cells, embryonic stem cells, insect cells, induced pluripotent stem cells, microbial cells, sperm cells, TCR cells, TILs, and tumor cells / cancer cells), [F] size of cell (< 5 µm, 5-10 µm, 10-15 µm, 15-25 µm, and > 25 µm), and [G] key geographical regions (North America, Europe and Asia-Pacific). We adopted a combination of top-down and bottom up approaches, backed by robust data and credible inputs from primary research, to estimate the likely size of the market, both in terms of value (USD billion) and volume (number of products).

Chapter 14 is a collection of executive insights of the discussions that were held with various key stakeholders in this market. The chapter provides a brief overview of the companies and details of interviews held with John Younger (Co-founder and Chief Technology Officer, Akadeum Life Sciences), Sean Hart (Chief Executive Officer and Chief Scientific Officer, LumaCyte), and Soohee Cho (Product Manager, Namocell).

Chapter 15 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 16 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 17 is an appendix, which contains the list of companies and organizations mentioned in the report.

LIST OF COMPANIES AND ORGANIZATIONS

The following companies / institutes / government bodies and organizations have been mentioned in this report.

1. 1087systems
2. 48Hour Discovery
3. 5AM Ventures
4. Abbott
5. AbbVie
6. Academia Sinica
7. Academic Medical Centre
8. Academy of Military Medical Sciences
9. Accelerate Diagnostics
10. ACEA Biosciences
11. AcouSort
12. Active Biotech
13. Adaptive Biotechnologies
14. Adelaide Research & Innovation
15. AdnaGen
16. ADS BIOTEC
17. Advanced Virus Detection Technologies Interest Group
18. Aegea Biotechnologies
19. Aenitis Technologies
20. Agency for Science, Technology and Research
21. Agilent Technologies
22. AIM Group International
23. AIMM Therapeutics
24. Akadeum Life Sciences
25. Albert Einstein College of Medicine
26. Alder BioPharmaceuticalss
27. Alexion Pharmaceuticals
28. Alkem Laboratories
29. Amazentis
30. Ambergen
31. American Institute of Health
32. Amgen
33. AnaptysBio
34. Ancera
35. Angel HQ
36. Angel Round Capital Fund
37. ANGLE
38. Ann & Robert H Lurie Children's Hospital of Chicago
39. ANSYS
40. Anzu Partners
41. ApoCell
42. Argonaut Manufacturing Services
43. arivis
44. Artiman Ventures
45. Ascent Bio-Nano Technologies
46. Ascus Biosciences
47. Astellas Pharma
48. Augusta University
49. Aurora Life Technologies
50. AVIVA Biosciences
51. Barts Cancer Institute
52. Base4 Innovation
53. Bay City Capital
54. Bayer
55. BC Cancer Agency
56. Beckman Coulter
57. Becton Dickinson
58. Beijing Genomics Institute
59. Beth Israel Deaconess Medical Center
60. Betta Pharmaceuticals
61. BGI Group
62. Biocept
63. Bioceptive
64. BioCrine
65. BioFluidica
66. BioInfleXion Point Partners
67. BIOKÉ
68. Biolidics
69. BioMEMS Resource Center
70. BioMimetic Therapeutics
71. Bio-Rad Laboratories
72. BIOSS
73. Bio-Techne
74. BioTheranostics
75. BioView
76. Boehringer Ingelheim
77. Boyalife Group
78. Bpifrance
79. Brigham and Women's Hospital
80. Bristol-Myers Squibb
81. Broad Institute
82. Bucher Biotec
83. C4 Therapeutics
84. California Institute of Technology
85. California NanoSystems Institute
86. Caltag Medsystems
87. Cambridge Consultants
88. Cambridge Enterprise
89. Canary Center at Stanford
90. Cancer Genetics
91. Cancer Institute of Greenville Health System
92. Cancer Metastasis Laboratory, University of Basel
93. Cancer Research UK Manchester Institute
94. CANCER-ID
95. Canon US Life Sciences
96. Capio Biosciences
97. Caris Life Sciences
98. Carnegie Mellon University
99. Case Western Reserve University
100. Catalyst Biosciences
101. Celgene
102. Cell Microsystems
103. Cell Signaling Technology
104. Cell.Copedia
105. Cellaviva
106. CellectCell
107. Cellenion
108. Cellix
109. CellMax Life
110. Celsee
111. Center for Advanced Medical Products
112. Centre Léon Bérard
113. Cephalon
114. Cesca Therapeutics
115. CFD Research
116. Chang Gung Memorial Hospital
117. ChemoCentryx
118. Chinese Academy of Medical Sciences
119. Cincinnati Children's Hospital Medical Center
120. Cipla
121. Clinomics
122. Columbia University
123. Cornell University
124. Corning
125. Creative BioArray
126. Creative Diagnostics
127. CREST
128. CRV International
129. CureGene
130. Cytonome
131. CytoVale
132. Cytovance Biologics
133. Dana-Farber Cancer Institute
134. Danaher
135. DAON BioSciences
136. Decheng Capital
137. Department of Biomedical Engineering, Lund University
138. Detroit Innovate
139. DiaSorin
140. Diffusion Capital Partners
141. Draper Laboratory
142. Duke University
143. eFFECTOR Therapeutics
144. Eisai
145. EKF Diagnostics
146. eLab Ventures
147. Eli Lilly
148. EMV Capital
149. Engender Technologies
150. Enlivex Therapeutics
151. Enterprise Angels
152. Epic Sciences
153. Evercyte
154. EXONBio
155. Fiona Stanley Hospital
156. Five3 Genomics
157. FloDesign Sonics
158. Florida Cancer Specialists and Research Institute
159. Fluidigm
160. France Innovation Scientifique et Transfert
161. French National Center for Scientific Research
162. Fudan University Shanghai Cancer Center
163. FusionX Ventures
164. GE Healthcare
165. GenapSys
166. Genentech
167. General Automation Lab Technologies
168. Genewiz
169. Genial Laboratory Automation
170. Genoa Ventures
171. Georgetown University
172. Georgia Tech Research Institute
173. Gilead Sciences
174. GILUPI
175. Glass Capital Management
176. GlaxoSmithKline
177. Glenmark Pharmaceuticals
178. GOM
179. Grace Bio-Labs
180. Greenwoods Asset Management
181. GRI Bio
182. Guangxi Academy of Sciences
183. Hahn-Schickard
184. Halcyon Biomedical
185. Halozyme Therapeutics
186. Harvard Stem Cell Institute
187. Harvard University
188. Horizon Discovery
189. Hubei Cancer Clinical Study Center
190. Humacyte
191. Humanitas Research Hospital
192. Hunan Agen Medicine Laboratory Technology
193. IBA Lifesciences
194. Icahn School of Medicine
195. ICE Angels
196. iCellate
197. ICREA
198. Ignyta
199. Illumina Ventures
200. IMEC
201. immatics biotechnologies
202. Immunomedics
203. ImmunoQure
204. Inabata
205. Inbiomotion
206. IncellDx
207. IncoCell Tianjin
208. Incyte
209. Inguran
210. Innate Pharma
211. Innovate UK
212. Innovative Biochips
213. Innovative Micro Technology
214. Inova
215. Institute of Cancer Research, London
216. Institute of Organic Chemistry and Biochemistry
217. Instrumentation Laboratory
218. Intrinsic LifeSciences
219. Invention Science Fund
220. Invest Michigan
221. Invetech
222. iPS Portal
223. Janssen Biotech
224. Japan Science and Technology Agency
225. Jiulongpo District People's Hospital
226. Jiva Sciences
227. John Hopkins University
228. John Wayne Cancer Institute
229. Jonsson Comprehensive Cancer Center
230. Karolinska Institute
231. Kataoka
232. Katholieke Universiteit Leuven
233. Keswick Ventures
234. Kiyatec
235. Koek Biotechnology
236. Kymab
237. LabCorp
238. Landos Biopharma
239. Lawson Health Research Institute
240. Leica Biosystems
241. LevitasBio
242. LG Electronics
243. LIDE Biotech
244. Life Technologies
245. Livzon Pharmaceuticals
246. London Business Angels
247. LPATH
248. LumaCyte
249. Luminex
250. LungLifeAI
251. Lupin
252. Mackay Memorial Hospital
253. Massachusetts Institute of Technology
254. Mayo Clinic Foundation
255. MD Anderson Cancer Center
256. MDxK
257. Medigen Biotech
258. MeMed Diagnostics
259. Memorial Sloan Kettering Cancer Center
260. Menarini Silicon Biosystems
261. Merck
262. Metabiota
263. Microbix Biosystems
264. MicroMedicine
265. Middle East Technical University
266. Mikro Biyosistemler
267. Mikro Systems
268. Millennium Pharmaceuticals
269. MilliporeSigma
270. Miltenyi Biotec
271. Morehouse School of Medicine
272. Morphotek
273. Mumbai Angels
274. Namocell
275. NanoCellect Biomedical
276. Nanosphere
277. NanoTag Biotechnologies
278. National Cancer Centre Singapore
279. National Cancer Institute
280. National Center for Emerging and Zoonotic Infectious Diseases
281. National Center for Nanoscience and Technology
282. National Institute for Health Research
283. National Institute for Innovation in Manufacturing Biopharmaceuticals
284. National Institute of Drug Abuse
285. National Institute of General Medical Sciences
286. National Institutes of Health
287. National University Hospital
288. National University of Ireland Galway’s Regenerative Medicine Institute
289. National University of Singapore
290. Naval Research Laboratory
291. Nektar Therapeutics
292. NeoDiagnostix
293. NeuroVision Pharma
294. New York Upstate Cord Blood Bank
295. New Zealand Venture Investment Fund
296. Newable Private Investing
297. NextGem
298. Nodality
299. Northeastern University
300. Northwestern University
301. Novartis
302. Novo Nordisk
303. Ohio State Innovation Foundation
304. On-chip Biotechnologies
305. Oregon Health & Science University
306. Organovo
307. Ortho Clinical Diagnostics
308. Orthohealing Center Management
309. Osaka University Venture Capital
310. Owl biomedical
311. OYAK
312. Pacific Biosciences
313. Pacific Channel
314. Packers Sanitation Services
315. Parkwalk Advisors
316. Partec
317. Penn State Research Foundation
318. PerkinElmer
319. Pfizer
320. Pharmaxis
321. Philips
322. Phywe
323. pluriSelect Life Science
324. Purdue Research Foundation
325. Qiagen
326. Quad Technologies
327. Qventures
328. R&D Systems
329. RareCyte
330. Real Tech Fund
331. Regeneron Pharmaceuticals
332. Regionalt Cancercentrum Stockholm-Gotland
333. RIKEN Bioresource Research Center
334. Riverside’s Highlander Venture Fund
335. Roche
336. Roswell Park Comprehensive Cancer Center
337. Rowan University
338. Rush University Medical Center
339. Samsung Medical Center
340. Sandoz
341. Sanford Burnham Prebys Medical Discovery Institute
342. Scholar Rock
343. ScreenCell
344. Seoulin Bioscience
345. Sequenom
346. Sequenta
347. Seventure Partners
348. Severance Hospital
349. Shilps Sciences
350. Shriners Hospitals for Children
351. Singapore General Hospital
352. Singapore Immunology Network
353. Singapore-MIT Alliance for Research and Technology
354. Singh Molecular Medicine
355. Singular BIO
356. Sir Charles Gairdner Hospital
357. Siwa Therapeutics
358. Skåne University Hospital
359. Sloan Kettering Institute
360. Sony Biotechnology
361. Southampton General Hospital
362. Sphere Fluidics
363. SpheriTech
364. SRI International
365. Stand Up To Cancer
366. Stanford University
367. Stanford Women's Cancer Center
368. StemBioSys
369. Stempeutics Research
370. Stony Brook University
371. Streck
372. Sumitomo Dainippon Pharma
373. Sutter Health
374. Syllogistech
375. SynGen Biotech
376. Syno Capital
377. Sysmex
378. Takeda Pharmaceutical
379. Tan Tock Seng Hospital
380. Targeted Technology Fund
381. Technical University of Denmark
382. Telegraph Hill Partners
383. Texas Stem Cell
384. The Fourth People's Hospital of Chongqing
385. Theranosis Life Sciences
386. Thermo Fisher Scientific
387. ThermoGenesis
388. ThinkCyte
389. Tisch Cancer Institute
390. Tokai Pharmaceuticals
391. TOMY Digital Biology
392. TorpedoDx
393. Tracon Pharmaceuticals
394. Trinity College Dublin
395. TumorGenesis
396. Twist Bioscience
397. Tyme
398. UCB Biopharma
399. UCLA Medical Center
400. Union Biometrica
401. United States Army Medical Research Institute for Infectious Diseases
402. United States Environmental Protection Agency
403. University of British Columbia
404. University of California
405. University of Chicago
406. University of Edinburgh
407. University of Illinois at Urbana-Champaign
408. University of Iowa Research Foundation
409. University of Kansas
410. University of Maryland
411. University of Miami
412. University of Michigan
413. University of Missouri
414. University of North Carolina
415. University of Notre Dame
416. University of Oxford John Radcliffe Hospital
417. University of Pennsylvania
418. University of Southern California Norris Comprehensive Cancer Center
419. University of Texas
420. University of Utah
421. University of Virginia School of Medicine
422. Uppsala University
423. US Department of Veterans Affairs
424. Vancouver Prostate Centre
425. Vanderbilt University
426. Vegenics
427. VentureSouth
428. Vertical Venture Partners
429. Vortex Biosciences
430. VWR
431. Wako Pure Chemical Industries
432. Washington University
433. Wego Medical Systems
434. Whitehead Institute for Biomedical Research
435. Woods Hole Oceanographic Institution
436. Wright State University
437. Xcell Biosciences
438. Yale University
439. Zeiss
440. Zhongnan Hospital of Wuhan University
441. Zomedica Pharmaceuticals
442. Zurich Instruments
443. ZymoGenetics